Camurus' FluidCrystal® injection depot can deliver therapeutic levels of drug substance over extended periods - tunable from days to months - from a single injection. The system is suitable for delivery of e.g. potent peptides and small molecules and offers a ready-to-use design facilitating easy administration.
The FluidCrystal® injection depot consists of a liquid lipid solution which on contact with minute amounts of water in the body transforms to a liquid crystalline gel. The gel effectively encapsulates the drug compound and when the depot is biodegraded the compound is slowly and steadily released in the body.
The FluidCrystal® system does not suffer from the limitations of high initial drug release, limited chemical and physical stability, complicated reconstitution and administration as well as costly manufacturing often associated with traditional microparticle based depot technologies.
Liquid crystalline gels can effectively encapsule a broad spectrum of substances, and because structure formation begins immediately after injection the release is slow and steady in the body.
The liquid crystalline structure have a protective effect for many sensitive substances which is a reason behind the high bioavilability that has been documented for the FluidCrystal® system.
The low viscosity in Camurus’ depot formulation makes the products based on the FluidCrystal® system easier to handle, easier to inject with fine needle and easier to manufacture, compared to conventional microparticle based depot.
The FluidCrystal® depot products are easily and conveniently administered in small doses by injection with a pre-filled standard syringe with a thin needle. The technology can also be complemented with a needle stick prevention device or an auto-injector. Camurus’ depot technologies make life easier for both patients and healthcare professionals. Products based on this technology are also well-suited for home-based administration by the patient or family members.
Camurus' FluidCrystal® topical bioadhesive delivery technology is applied on topical surfaces where it spreads to form a thin bioadhesive film which protects the biosurface and can be used to locally release active drug substances. The system is suitable for prolonged local release of e.g. peptides and small molecules on oral, nasal, vaginal and rectal mucosa as well as on the skin.
The formulation is applied as a low viscous liquid to topical surfaces, where it spreads to form a thin bioadhesive film after absorption of minute amounts of water. The nanostructure of the film can be tuned for optimum release and bioadhesive characteristics. The formulation has a high solubilising capacity, which allows small dosage volumes to achieve therapeutic effects with the active ingredient.
FluidCrystal® topical bioadhesive is compatible with several applicators, such as disposable pipettes, tubes and spray bottles.
The commercially available product episil® is based on the FluidCrystal® topical delivery system.
FluidCrystal® nanoparticles addresses bioavailability limitations for amphiphilic and lipophilic drugs or biodegradation sensitive drugs.
FluidCrystal® nanoparticles are usually water-based and comprise a stable emulsion of nanoparticles with a liquid crystalline structure. The technology has been designed to increase the bioavailability of amphiphilic and lipophilic drugs with low aqueous solubility and biodegradation-sensitive drugs such as peptides and proteins.
Products based on this technology are either preformed to stable dispersions for intravenous, subcutaneous, intramuscular or intracavital injection, or applied to the skin or mucous membranes in spray form.